➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts

Last Updated: September 28, 2021

DrugPatentWatch Database Preview

Details for Patent: 9,101,615

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,101,615 protect, and when does it expire?

Patent 9,101,615 protects VARUBI and is included in one NDA.

This patent has twenty-six patent family members in fourteen countries.

Summary for Patent: 9,101,615
Title:Intravenous formulations of neurokinin-1 antagonists
Abstract: Pharmaceutical compositions for intravenous administration comprising the compound of Formula I ##STR00001## or pharmaceutically acceptable salts, hydrates or prodrugs thereof are described herein. Methods of preparing the pharmaceutical compositions and methods for treating nausea and/or emesis with the pharmaceutical compositions are also described herein.
Inventor(s): Wan; Jiansheng (Warren, NJ), Gupta; Pranav (Short Hills, NJ), Monteith; David (Pittstown, NJ), Bhattacharya; Soumendu (East Windsor, NJ)
Assignee: OPKO Health, Inc. (Miami, FL)
Application Number:12/855,889
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;

Drugs Protected by US Patent 9,101,615

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Tersera VARUBI rolapitant hydrochloride EMULSION;INTRAVENOUS 208399-001 Oct 25, 2017 DISCN Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial PREVENTION OF DELAYED NAUSEA AND VOMITING ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,101,615

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2010282483 ⤷  Free Forever Trial
Brazil 112012003263 ⤷  Free Forever Trial
Canada 2770403 ⤷  Free Forever Trial
China 102573475 ⤷  Free Forever Trial
China 105503870 ⤷  Free Forever Trial
European Patent Office 2464230 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.